



RÉPUBLIQUE
FRANÇAISE

Liberté
Égalité
Fraternité

Inserm



La science pour la santé _____
_____ From science to health

Inserm presentation





RÉPUBLIQUE
FRANÇAISE

*Liberté
Égalité
Fraternité*

Inserm



La science pour la santé _____
_____ From science to health

Inserm is the only public
research organization in France
entirely dedicated to health.





RÉPUBLIQUE
FRANÇAISE

*Liberté
Égalité
Fraternité*

Inserm



La science pour la santé _____
_____ From science to health

Our objective: to promote the health of all by advancing knowledge on living organisms and their diseases, and by developing innovation.



Content

- Address major biomedical research challenges
- Take action to improve the health of all
- Disseminate knowledge for the benefit of all



RÉPUBLIQUE
FRANÇAISE

*Liberté
Égalité
Fraternité*

Inserm



La science pour la santé _____
_____ From science to health

Address major biomedical
research challenges



Be a reference in biomedical research



In Europe and worldwide

- More than 9,000 copublications with almost 190 international partners in 2024
- 40 strategic partnership agreements
- 78 collaboration, projects, networks and platforms over 5 continents

In France

- 263 research units
- 50 service units
- 37 clinical investigation centers



15,832 staff

- 5,046 civil servants (2,201 researchers, ATIP-Avenir contracts included)
- 4,172 contract staff and temporary workers (incl. ATIP-Avenir contracts)
- > 49 ATIP-Avenir contracts
- 6,614 teacher-researchers and hospital teachers

An initial budget of €1,335.5 million

- €729 million from government subsidies
- €606.5 million from internal resources

* in 2026



Patents and licenses

- A portfolio of 2,568 patent families
- 64 new license agreements signed
- 241 R&D partnerships

Be a reference in biomedical research (2)



In Europe

- No. 1 academic applicant in the biomedical sector in Europe
- No. 1 European applicant in the pharmaceutical sector
- No. 3 European applicant in the biotechnology sector

Horizon Europe since 2021:

- ERC: 88 projects, 2^d French grant winner
- Marie Skłodowska Curie Actions: 54 projects, including 32 coordination
- Health Cluster: 88 projects, including 25 coordination, among which Erdera partnership on rare diseases and HERA partnership on emergency preparedness
- EIC: 19 projects, including 2 coordination
- Infrastructure: participation in 12 projects



Close dialogue

with over 350 patient organizations for

- participatory research
- meetings and debates between patients and researchers




13,147 original articles

(2024 publications)

- Address major biomedical research challenges

Make changes to adapt



- Address major biomedical research challenges

Our organization



Chairman and CEO
Didier Samuel



Vice CEO
for Strategy
Elli Chatzopoulou



Vice CEO
for Administration
Damien Rousset



Executive Director
Carine Delrieu



Executive Director
Programming Agency
Franck Mouthon

Professional Ethics Board
Ethics Committee
Ethics Evaluation Committee
Office for Research Integrity
Think Tank Network with Patient
Organizations (GRAM)
History Committee

Management Board
Scientific Advisory Board
Specialized Scientific Committees
Research Support Committee

General Directorate

Thematic institutes

- Cancer
- Cell biology, development and evolution
- Genetics, genomics and bioinformatics
- Health Technologies
- Immunology, inflammation, infectious diseases and microbiology
- Molecular and structural basis of living organisms
- Neurosciences, cognitive sciences, neurology, psychiatry
- Pathophysiology, metabolism, nutrition
- Public health

Divisions

- Communication
- Financial Affairs
- Human Resources
- Information Systems
- Legal Affairs
- National and Foreign Affairs
- Open Science
- Program Assessment
- Strategic Program
- Accounting Department

Regional Offices

- Auvergne-Rhône-Alpes
- Est
- Grand Ouest
- Île-de-France (4)
- Nord-Ouest
- Nouvelle-Aquitaine
- Occitanie Méditerranée
- Occitanie Pyrénées
- Provence-Alpes-Côte d'Azur and Corsica

- Address major biomedical research challenges

Our presence in France (2)

14 | main research universities partner with Inserm



Our main partners in France and abroad

- **37** universities
- A key partner of **14** research universities in which are IDEX and I-sites
- Research units in **33** teaching hospitals
- National research institutions: CNRS / Inrae / Inria / IRD / INED...
- French top graduate schools: ENS, ESPCI, EHESS, École polytechnique, EHESP, École des Mines, ENVA...
- Industry: Astra Zeneca/MedImmune, MSD Avenir, Sanofi, AdBio Partners...
- Foundations and associations: Fondation Bettencourt Schueller, FRM...
- European and international academic institutions: Helmholtz, NIH...

Our partner laboratories abroad

- Besides the numerous informal scientific collaborations its research teams launch with foreign laboratories over the five continents, Inserm counted in 2025:
 - **40** key international partnerships and joint labs,
 - **3** thematic coordination programs, with **13** partners,
 - **4** international research platforms in global health,
 - **15** first step projects and **54** international research programs,
 - **2** offices abroad
- Inserm also works with **9** partner countries through ANRS MIE (Emerging Infectious Diseases).



RÉPUBLIQUE
FRANÇAISE

*Liberté
Égalité
Fraternité*

Inserm



La science pour la santé _____
_____ From science to health

Take action to improve
the health of all



Programming and steering national health research



Objectives

To make the research and innovation ecosystem better able to respond to the major challenges and transitions facing the health sector. To achieve this, the **Health Research Programming Agency** will strengthen coordination between the relevant stakeholders, and help prioritize and define research programs deemed strategic because they have a high societal impact and are of sovereign interest. Once these programs have been approved by the French government, the Agency orchestrates their national management.

Missions

- Establish a forward-looking vision to support the induction of innovative and ambitious research programs, based on priority scientific issues in healthcare
- Build interdisciplinary expertise in the field of biomedical research
- Ensure the coordination between priority programs, with site policies, national and European research infrastructure roadmaps, European initiatives, and across the entire continuum of funding and action in priority areas

Roadmap

- Develop three new priority research programs (neurodegenerative diseases, chronic inflammatory diseases, transplantation)
- Finalize the France Vaccines program
- Manage the research component of the National Acceleration Strategy on Health Prevention
- Build an interdisciplinary end-of-life research program
- Contribute to national and European roadmaps for research and technological infrastructures and facilities
- Develop the Agency's expertise and prospective action

- Take action to improve the health of all

Organizing priority health research

Inserm pilots or co-pilots the eight priority health research programs and facilities financed by France 2030, linked to national strategies.

Exploration strategies:

- Precision psychiatry (M€80, with CNRS)
- Cellular identities and destinies (M€80, with CNRS)
- Organs and organoids on chips (M€48.4, with CNRS and CEA)

Acceleration strategies:

- Emerging infectious diseases (M€70, with ANRS EID)
- Biotherapies and bioproduction of innovative therapies (M€80, with CEA)
- Digital health (M€60, with Inria)
- Food systems, microbiomes and health (M€58, with INRAE)
- Women's health, couples' health (M€25)

- Take action to improve the health of all

Supporting breakthrough in health research

Inserm leads the national funding program for high-impact, high-risk health research, Impact santé, supported by France 2030.

Objective: identify and provide decisive support for fundamental and applied health research projects that could generate strategic breakthroughs for France over the coming decades, whether in terms of concepts, technologies or methodologies

Budget: M€30 in 2024


Beneficiaries: all health researchers, regardless of affiliation

Missions:

- Accompanying and accelerating projects already considered sufficiently mature to produce breakthrough research (maximum M€3 per project)
- Detection and seed funding (€150,000 per project) of exploratory projects which, after a maturation phase, are likely to become breakthrough research projects


- Take action to improve the health of all

Our missions for health




- Take action to improve the health of all

Our fields of activity and expertise




- Take action to improve the health of all

Cohorts and epidemiological studies



- Take action to improve the health of all

A continuum from basic to clinical, therapeutic, and public health research




Value creation activities which are bearing fruit

- **2,568** patent family's portfolio
- **143** new patent families in 2025
- An annual budget of **€2 M** to fund project maturation or proof of concept
- A maturation budget reaching **€29,4 M** invested in **514** projects since 2009
- **€715 M** industrial partnerships since 2006 (research contracts, licenses)
- **~ €30 M** per year from licensing agreements
- Over **400** technologies and research tools available for licensing
- Strategic alliances with MSDAVENIR, Astra Zeneca/MedImmune, Sanofi, AdBio Partners...
- **10** startups created each year via Inserm Transfert (Inserm's subsidiary)
- Partnerships with SATTs


- Take action to improve the health of all

Inserm & Inserm Transfert in EPO rankings


1st in the Pharmaceutical sector



11th in France across all sectors



3rd in the biotechnology sector



- **No. 1** European applicant in the pharmaceutical sector
- **No. 3** European applicant in the biotechnology sector
- **No. 1** European research academic institution in the biomedical sector
- **2,568** patent families as of 31/12/2025

- Take action to improve the health of all

Inserm Transfert: partnering with industries

A privileged partner of major industrials, mid-size, SME, involved in human health, at the international level, among which:



- Take action to improve the health of all

Inserm spin-offs based on inventors as drivers



Major discoveries

Since its foundation in 1964, Inserm has played a part in many key, historic medical advances, such as:

- **the first prenatal diagnostic tests;**
- **understanding the HLA system** and the ensuing immune reactions;
- **the first in vitro fertilization;**
- **radiotherapy for cancer;**
- **the first skin graft;**
- **deep brain stimulation** in the treatment of Parkinson's disease;
- **gene therapy** in the treatment many diseases;
- **innovative technologies** like bioprinting, ultrasound, imaging organoids...
- **the Nutri-Score** informing on the nutritional quality of foods



RÉPUBLIQUE
FRANÇAISE

*Liberté
Égalité
Fraternité*

Inserm



La science pour la santé _____
_____ From science to health

Disseminate knowledge
for the benefit of all



- Disseminate knowledge for the benefit of all

Our ethics committee to reflect on innovative research and to shed light on debates

Since 1999, Inserm ethics committee has focused on ethical questions in emerging areas of medical innovation

- Publication of multiples notes on genome editing and participation in the creation of ARRIGE (Association for Responsible Research and Innovation in Genome Editing) in 2018
- Launch in 2022 of Volrethics to define common international ethical rules to protect healthy volunteers in biomedical research and publication of a dedicated global ethics charter, signed in 2025
- Think tanks on gender and health research, research on the human embryo, genomic medicine, neurotechnology in education, organoids and organs on chips...

- Disseminate knowledge for the benefit of all

Collective expert reviews and contribution to public health policy

Inserm fulfils its mission of expertise provision and knowledge transfer to decision-makers in the field of public health by providing the scientific insight required to take decisions on public health policy issues.



- Disseminate knowledge for the benefit of all

Our work with patient organizations

Towards research in partnership with patient organizations and civil society collectives

- Promote meetings and direct dialogue between researchers and collectives
- Act for the structuring, coordination and animation of participatory research projects
- Help to better take into account these projects in the assessment of researchers and structures
- Facilitate access to scientific information for society

- Disseminate knowledge for the benefit of all

Our presence in the service of public information



inserm.fr

9,100,000

visits



477,500

followers



192,100

followers



53,500

followers



26,900

followers



4,600

followers



28,900

followers



Live lectures and
30' Santé broadcast

134,000 views



Public events
1,700,000
participants and views

Meetings and training on
participatory research

280 participants



Canal Détox
information videos and articles
2,200,000 pages viewed



RÉPUBLIQUE
FRANÇAISE

*Liberté
Égalité
Fraternité*

Inserm



La science pour la santé _____
_____ From science to health

#FromScienceToHealth

